menu

What Factors Impact Use of ADCs in Special Patient Populations with Metastatic TNBC?

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Triple-Negative Breast Cancer (TNBC): Choosing the Right ADC for the Right Patient

What Factors Impact Use of ADCs in Special Patient Populations with Metastatic TNBC?

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs across the continuum of Triple Negative Breast Cancer (TNBC).

    In addition, a patient education solution is available to complete the curriculum by providing clinician-developed videos. Clinicians electronically prescribe these convenient videos to patients. Expert providers answer top questions faced by patients with breast cancer in a trustworthy, evidence-based format. 

    Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including oncologists, pathologists, oncology nurses, pharmacists, and advanced practitioners as well as other clinicians involved in the management of patients with metastatic breast cancer.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Explain the rationale for varying levels of ADC target positivity required for ADC efficacy and treatment eligibility
    • Identify patients with TNBC who are optimal candidates for ADCs
    • Develop evidence-based treatment strategies using ADCs in metastatic TNBC
    • Apply knowledge of barriers to access, care, and treatment that exist in the care of minority patients diagnosed with metastatic TNBC
    • Differentiate advantages of ADCs in special populations of patients with metastatic TNBC
    • Identify strategies for improving adherence through adverse effect management
  • Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. 

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Sara A Hurvitz, MD, FACP, chair for this educational event, receives the research grant and manages the funds for Ambrx, Amgen,  Arvinas, Astra Zeneca, Bayer, Cytomx, Daiichi-Sankyo, Dantari, Dignitana, Genentech/Roche, G1-Therapeutics, Gilead, GSK, Immunomedics, Eli Lilly, Macrogenics, Novartis, OBI Pharma, Orinove, Pfizer, Phoenix Molecular Designs, Ltd., Pieris, PUMA, Radius, Samumed, Sanofi, Seattle Genetics/Seagen, Zymeworks, Greenwich life Sciences, Orum.   

    Sara M. Tolaney, MD, MPH, faculty for this educational event, receives the research grant and manages the funds for    
    AstraZeneca, Eli Lilly, Merck, Novartis, Pfizer, Genentech/Roche, OncoPep, Gilead, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Cyclacel, Sanofi, Seattle Genetics; and receives consulting fees for Daiichi Sankyo, CytomX, 4D Pharm, BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Myovant, Umoja Biopharma, Menarini/Stemline, Aadi Bio, Artios Biopharmaceuticals, Incyte Corp, Zetagen, and Bayer. 

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Megan Reimann, PharmD, BCOP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    Total CME, LLC. Planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go, you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from Gilead Sciences, Inc.

    Jointly provided by Global Learning Collaborative (GLC) and Total CME, LLC.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 7/21/2023 through 7/21/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.


    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule18 Jul 2024